Under the microscope: Antisense Therapeutics (ASX:ANP) and Neuren Pharmaceuticals (ASX:NEU)

from Morgans Under the Microscope · host Morgans Financial Limited

Morgans analyst Iain Wilkie discusses the healthcare team's initiation of coverage for Antisense Therapeutics (ASX:ANP) and highlights Neuren Pharmaceuticals (ASX:NEU) as a stock with key catalysts ahead.Check out more from Morgans:Visit the Morgans website: www.morgans.com.auCheck out our blog: www.morgans.com.au/BlogOn Facebook: www.facebook.com/MorgansAUOn Instagram: www.instagram.com/morgans.australiaOn Twitter: twitter.com/morgansAU

Episode metadata supplied by the publisher feed · Published Jan 11, 2021

Embed this episode

Attribution link and audio player

NOW PLAYING

Under the microscope: Antisense Therapeutics (ASX:ANP) and Neuren Pharmaceuticals (ASX:NEU)

0:00 5:03

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Morgans Under the Microscope?

This episode is 5 minutes long.

When was this Morgans Under the Microscope episode published?

This episode was published on January 11, 2021.

Can I download this Morgans Under the Microscope episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!